Over the years, accumulating evidence has indicated that d-serine represents the main endogenous ligand of NMDA (N-methyl-d-aspartate) receptors. In the brain, the concentration of d-serine stored in cells is defined by the activity of two enzymes: serine racemase (responsible for both the synthesis and degradation) and d-amino acid oxidase (which catalyses d-serine degradation). The present review is focused on human damino acid oxidase, discussing the mechanisms involved in modulating enzyme activity and stability, with the aim to substantiate the pivotal role of d-amino acid oxidase in brain d-serine metabolism.
Introduction
The peroxisomal FAD-dependent enzyme DAAO (D-amino acid oxidase, EC 1.4.3.3) is considered the paradigm of the dehydrogenase-oxidase class of flavoproteins. One of the most interesting aspects of these enzymes is that they use complex steric control to achieve a very high stereospecificity of the reaction they catalyse [1] . In fact, DAAO catalyses the strictly stereospecific oxidative deamination of D-amino acids to give the corresponding imino acids, hydrogen peroxide and ammonia ( Figure 1A ). DAAO putative genes and enzymatic activity have been identified in most eukaryotic organisms (the main exception being represented by plants). In addition, recombinant DAAOs from a variety of sources, ranging from yeast to mammals, have been expressed and purified [2] . In mammals DAAO is mainly present in kidney and liver, but it is also enriched in the brain where its role remained elusive until significant concentrations of D-amino acids (i.e. D-alanine, D-serine, D-leucine and D-proline) were detected [3] . Among them D-serine is by far the most abundant [4, 5] . This 'atypical' signalling molecule binds to the 'strychnineinsensitive glycine modulatory site' of the NMDAR [NMDA (N-methyl-D-aspartate) receptor] [6] .
D-Serine plays a key role in crucial physiological processes such as brain development, neuronal cell migration, excitotoxicity, and learning and memory. It is critical for NMDAR activation and probably significantly contributes to the capacity of neural networks to express long-lasting functional plasticity ( [7] and references therein). Moreover, D-serine affects functional NMDAR subunit composition at different levels, ranging from synthesis, to trafficking and activation [8, 9] .
Several studies have indicated that D-serine levels are decreased in schizophrenic patients [10, 11] , and D-serine greatly ameliorated the symptoms of this complex disease when administered together with conventional neuroleptics [12] . Accordingly, polymorphisms and haplotypes in the genes encoding DAAO and its interactor pLG72 (also known as D-amino acid oxidase activator or DAOA), as well as the D-serine synthetic enzyme SR (serine racemase, EC 5.1.1.18), have been correlated with an increased schizophrenia susceptibility [13] . Unravelling the factors modulating the functionality of the enzymes involved in the regulation of Dserine cellular levels (in particular DAAO) is of outstanding interest, since this might improve our understanding of the molecular mechanisms involved in complex pathological conditions such as schizophrenia.
DAAO and d-serine metabolism
The key enzyme responsible for D-serine synthesis is the PLP (pyridoxal phosphate)-dependent enzyme SR, which converts L-serine into the D-isomer [14, 15] ; the neuromodulator is then presumably degraded by both SR itself, which also catalyses the α,β-elimination of water from L-and D-serine with the production of pyruvate and ammonia [16, 17] , and DAAO [13] .
Recently, Wolosker [18] in his 'serine-shuttle model' suggested that D-serine is synthesized in neurons by SR, released upon membrane depolarization and subsequently shuttled to astrocytes for storage and activity-dependent release; the latter cells express low levels of SR, and thus are ideally suited for this task effectively sequestering D-serine and preventing its excessive degradation by SR. On the basis of these considerations, the proposed model indirectly assigns to DAAO a key role in regulating the D-serine concentration in glial cells, although significant levels of flavoenzyme were also observed in neurons [19] .
Although the biological relevance of DAAO in the regulation of D-serine cellular storage/turnover (and thus, indirectly, of its availability at the synapses) has occasionally been questioned, indirect data from studies performed in transgenic animals were fundamental to substantiate the proposed physiological role of the flavoenzyme. A substantial increase (severalfold) in the concentrations of D-serine and other D-amino acids was detected in ddY/DAAO − / − mice, in which DAAO activity is lost due to an inactivating point mutation (G181R) [20, 21] . Interestingly, these mice display behavioural phenotypes consistent with altered NMDAR signalling, including decreased stereotypy and ataxia elicited by MK-801 [22, 23] , and enhanced spatial learning and LTP (long-term potentiation) in the hippocampus [24] . A similar effect was achieved by oral or systemic administration of DAAO inhibitors to normal rodents, which elevated central D-serine levels [25, 26] and increased NMDAR-mediated function [27] . These observations support a major role for DAAO in D-serine metabolism.
Human DAAO biochemical properties
Recombinant hDAAO (human DAAO) was expressed in Escherichia coli and purified as a stable and active holoenzyme [28, 29] . The protomer (347 residues, ∼40 kDa) displays the classical αβ-structure of FAD-containing flavooxidases constituted by two domains, the FAD-binding domain and the interface domain ( Figure 1B) , and shows the typical absorbance spectrum and properties of this class of flavoenzymes [2, 13, 28] . The reaction catalysed by hDAAO follows a sequential kinetic mechanism in which the rate-limiting step is represented by the product release from the re-oxidized enzyme, analogous to porcine DAAO, although the rate of flavin reduction is lower for the human enzyme [28] . hDAAO differs from other known mammalian homologues because of its stable homodimeric state (even in the apoprotein form, all other known DAAO apoproteins are stable 40 kDa monomers) and a weak interaction with the FAD cofactor ( Table 1 ). The dimeric state has been related to the high concentration of charged residues at the dimerization interface, which is largely conserved in the apoprotein form: this region is a 'hotspot' for mutations, with a substitution frequency ∼2-fold higher than for the rest of the protein [30] . Owing to the low affinity for the FAD cofactor, the recombinant hDAAO exists in solution as an equilibrium between the active holoenzyme and the inactive apoprotein. Indeed, a 20-fold tighter interaction with FAD is observed when a ligand mimicking the substrate (e.g. benzoate; Table 1 ) is present at the active site of the enzyme [28] . This feature may represent a mechanism evolved to increase the amount of the active enzyme only in the presence of high concentrations of the physiological substrate (D-serine in the brain), in order to prevent its excessive degradation. hDAAO apoprotein can be distinguished from the holoenzyme form by a more 'relaxed' tertiary structure, whereas the secondary structure is highly similar. This makes apo-hDAAO more liable to proteolytic digestion and thermal denaturation [31] . Addition of FAD to the apoprotein quickly results in a compact holoprotein with increased resistance to trypsin cleavage and denaturation. This further supports that the low affinity for the cofactor represents a mechanism to regulate flavoenzyme activity.
Substrate specificity and kinetc properties
The hDAAO active site is striking for its simple set-up ( Figure 1C) ; the active-site residues are not directly involved in the chemical steps of catalysis, but are fundamental for fixing the substrate in the correct orientation to enable efficient oxidation (orbital steering) [32] . The interaction between the ligand and the side chains of the DAAO active site can be divided into two groups [33] : (i) the first group encompasses interactions (mainly hydrogen bonds and electrostatic) between the 'invariable part' of the substrate D-amino acid and charged or polar residues of the active site, and (ii) the second group of interactions (mainly van der Waals interactions) involves the substrate side chain and hydrophobic side chains of residues located in a pocket on the opposite side with respect to the carboxy group. Since this region of the active site is mainly hydrophobic, hDAAO shows a preference for D-amino acids possessing a bulky and hydrophobic side chain (such as D-tryptophan, D-phenylalanine, D-tyrosine and D-proline) and a very low activity towards charged amino acids. Also, a relatively low catalytic efficiency and substrate affinity on the physiological substrate D-serine has been observed (k cat /K m = 0.40 s − 1 ·mM − 1 ; see Table 2 ). Interestingly, the human enzyme is also active on the alternative NMDAR co-agonist glycine and the agonist D-aspartate; however, the relative affinity for these substrates is very low (k cat /K m = 0.005 and 0.003 s − 1 ·mM − 1 respectively); in contrast, no activity is evident on NMDA (Table 2 ). In addition, hDAAO catalyses the oxidation of D-DOPA (D-3,4-dihydroxyphenylalanine) into dihydroxyphenylpyruvic acid [34] (Table 2) . DAAO was also reported to catalyse the conversion of D-KYN (D-kynurenine) into KYNA (kynurenic acid), a neuroactive metabolite of the kynurenine pathway of tryptophan degradation with antioxidant properties [35] ; previous investigations provided evidence that DAAO may contribute to KYNA production in human and rat brain [36, 37] .
Modulation of hDAAO functionality

Inhibitor binding
Although classical DAAO inhibitors (e.g. benzoate) have been known for a long time, the discovery that DAAO and D-amino acids are implicated in several physiological (and pathological) processes in the mammalian CNS (central nervous system) prompted a quest for more effective hDAAO inhibitors that potentially could be employed as drugs. The combined use of structural bioinformatics, highthroughput screening and structural biochemistry studies yielded to the identification of several high-affinity DAAO inhibitors (Table 2 ): (i) the hetero(bi)cyclic carboxylic acids, such as 5-methylpyrazole-3-carboxylic acid (AS057278) (IC 50 = 910 nM) [25] , 4H-furo[3,2-b]pyrrole-5-carboxylic acid (IC 50 = 141 nM) [38] and 4H-thieno[3,2-b]pyrrole-5-carboxylic acid (IC 50 = 145 nM) [39] ; (ii) a series of compounds based on benzo[d]isoxazol-3-ol, the most potent of which was CBIO (6-chlorobenzo[d]isoxazol-3-ol) (IC 50 = 188 nM) [40] ; and (iii) the very potent hDAAO inhibitor 3-hydroxyquinoline-2-(1H)-one (IC 50 = 4 nM) and its analogues [26] . Their main properties and pharmacokinetics have been reviewed recently [33] . The mode of binding of these inhibitors resembles that observed for the substrate ( Figure 1C ): the carboxy group [or the corresponding OH and C=O groups in 3-hydroxyquinolin-2(1H)-one] of the inhibitor interacts with Arg 283 and Tyr 228 , whereas a hydrogen-bond donor of the inhibitor binds Gly 313 . The remaining part of the inhibitor interacts with the hydrophobic region of the active site. Tyr 224 contributes greatly to the overall binding; its side chain is shifted towards the inner part of the active site: in this orientation the aromatic inhibitor is sandwiched between the aryl chain of this residue and the re-face of FAD isoalloxazine, forming strong π -π stacking interactions. Notably, theoretical studies [41] have shown that the best binding energy is obtained when the aromatic rings are slightly displaced, as observed in the case of the ligand 3-hydroxyquinoline-2-(1H)-one (K d = 0.013 μM, Table 2 ) [26], and not when they are perfectly stacked, such as in the hDAAO-benzoate complex (K d = 7 μM, Table 2 ) [30] . Another well-known hDAAO inhibitor is CPZ (chlorpromazine), a drug widely used for the treatment of schizophrenia. CPZ competes with FAD for the binding to hDAAO apoprotein (K d = 5 μM; K i = 0.7 mM, Table 2 ) [42, 43] . Ligand binding profoundly affects hDAAO stability: benzoate binding protects the holoenzyme from thermal denaturation and proteolysis by increasing the amount of hDAAO holoenzyme present in solution, as the result of a 27-fold decrease in the K d for FAD binding. Similar effects were observed in the presence of the pseudosubstrate trifluoro-D-alanine (CF 3 -D-alanine, K i = 3 μM): the hDAAO substrate-binding site is formed in the apoprotein form of the enzyme, as demonstrated by the great change in protein fluorescence and thermal stability in the presence of D-serine or of an active-site ligand [31] . On the other hand, the enzyme susceptibility to proteolysis was enhanced by CPZ binding: the FAD-competitive inhibitor seems to favour a protein conformation resembling that of the apoprotein form. The different alterations to hDAAO stability and cellular concentration exerted by benzoate and CPZ might affect the in vivo levels of D-serine differently over time [31] .
hDAAO-pLG72 interaction
In 2002, Chumakov et al. [44] proposed that the small protein pLG72 (18 kDa) encoded by the primate-specific gene G72, identified in humans as a putative schizophrenia candidate gene, interacts with DAAO, modulating its functionality. Subsequently, in slices from human brain cortex, we identified hDAAO and pLG72 in the same astrocytes and reported on the co-immunoprecipitation of the two proteins from human cortex extracts [42] . We also demonstrated that pLG72 binding to both the holo-and apo-protein forms of hDAAO yields an ∼200 kDa complex constituted by two hDAAO homodimers (2×80 kDa) and two pLG72 molecules (2×20 kDa) [42] . pLG72 binding does not affect the kinetic parameters of the reaction catalysed by hDAAO on D-serine, the affinity for the cofactor, and the rate constant of FAD binding to the apoprotein. The main effect of the interaction is a shorter time course of hDAAO inactivation: the complex formation modifies the tertiary structure of the flavoenzyme and results in a time-dependent inactivation [42] . As a matter of fact, limited proteolysis studies show that the presence of a stoichiometric amount of pLG72 increases the rate of hDAAO holoenzyme degradation, a destabilization most apparent at increasing pLG72 concentrations (see [31] ). None of the above-mentioned hDAAO small ligands (FAD, benzoate, D-serine or CPZ) modified hDAAO-pLG72 complex formation. Binding of FAD, benzoate and CF 3 -D-alanine counteracts the destabilizing effect of pLG72, whereas CPZ binding further increases susceptibility to proteolysis [31] .
We further provided evidence that the cellular concentration of D-serine depends on the expression of the active form of the flavoenzyme [42] , and that the destabilization effect of the pLG72 interaction on the half-life of hDAAO is also apparent at the cellular level [45] . Interestingly, although hDAAO is a peroxisomal enzyme, the newly synthesized flavoprotein is transitorily present in the cytoplasm (before being delivered to the organelles) where it can interact with pLG72, which we supposed to be exposed on the cytosolic surface of the mitochondria external membrane [45] . Taken together, we propose that pLG72 binding switches off hDAAO activity and, under normal conditions, prevents glial D-serine from being fully degraded.
These findings are in agreement with our previously proposed model explaining the role of hDAAO and pLG72 in modulating the D-serine cellular level during the onset of schizophrenia [42] : a decrease in pLG72 expression, producing an anomalously high level of hDAAO activity might result in an excessive decrease in the local concentration of D-serine.
Concluding remarks
Maintaining physiological concentrations of D-serine, and thus the fine balance between synthesis and degradation, is crucial for the brain to develop and function correctly. Therefore it is of utmost importance to clarify the complex processes that are in play in D-serine metabolism, For this reason, the factors (effector molecules and regulatory interacting proteins) affecting hDAAO functionality should be investigated in greater depth. This will help in designing new and more effective drugs for the treatment of pathologies, conditions such as schizophrenia, in which an imbalance in D-serine levels, possibly related to alterations in hDAAO activity, probably occurs and results in NMDAR dysfunction.
